United Therapeutics Corporation (NASDAQ:UTHR) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of United Therapeutics Corporation (NASDAQ:UTHR) have earned a consensus rating of “Moderate Buy” from the thirteen analysts that are currently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $646.00.

Several research firms have commented on UTHR. JPMorgan Chase & Co. upped their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Bank of America cut their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Morgan Stanley set a $515.00 price objective on United Therapeutics in a research report on Thursday, August 6th. Royal Bank Of Canada decreased their price objective on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Finally, Weiss Ratings cut United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th.

Insider Activity

In other news, CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $545.80, for a total transaction of $5,185,100.00. Following the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $22,111,995.40. This trade represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 346,053 shares of company stock valued at $180,494,891 over the last ninety days. Corporate insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On United Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of UTHR. Arjuna Capital grew its holdings in United Therapeutics by 2.8% during the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock worth $393,000 after acquiring an additional 18 shares during the period. Sage Rhino Capital LLC lifted its holdings in United Therapeutics by 5.1% in the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock valued at $281,000 after acquiring an additional 23 shares during the last quarter. Bryn Mawr Trust Advisors LLC lifted its holdings in United Therapeutics by 5.4% in the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock valued at $276,000 after acquiring an additional 24 shares during the last quarter. Meeder Advisory Services Inc. boosted its position in shares of United Therapeutics by 4.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock valued at $392,000 after purchasing an additional 26 shares in the last quarter. Finally, Kera Capital Partners Inc. boosted its position in shares of United Therapeutics by 6.1% during the 1st quarter. Kera Capital Partners Inc. now owns 471 shares of the biotechnology company’s stock valued at $279,000 after purchasing an additional 27 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

Shares of UTHR opened at $494.63 on Wednesday. United Therapeutics has a 1 year low of $408.75 and a 1 year high of $609.35. The company has a market cap of $21.21 billion, a price-to-earnings ratio of 17.70, a price-to-earnings-growth ratio of 2.48 and a beta of 0.56. The firm has a fifty day moving average of $515.48 and a 200-day moving average of $540.50.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same quarter last year, the company earned $6.41 EPS. Analysts predict that United Therapeutics will post 26.21 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.